Opus Genetics (IRD) Equity Average (2011 - 2026)

Opus Genetics (IRD) has 16 years of Equity Average data on file, last reported at -$15.2 million in Q1 2026.

• Equity Average for Q1 2026 came in at -$15.2 million, down 358.44% year-over-year; the trailing twelve-month figure through Mar 2026 was -$15.2 million (down 358.44% YoY), and the FY2025 annual result was $11.0 million, down 61.02% from the prior year.
• Equity Average fell to -$15.2 million in Q1 2026 per IRD's latest filing, from $10.7 million in the prior quarter.
• Over five years, Equity Average peaked at $50.1 million in Q4 2023 and troughed at -$15.2 million in Q1 2026.
• A 5-year average of $25.2 million and a median of $20.5 million in 2024 frame the typical range for Equity Average.
• The sharpest annual moves came in 2022 and 2026: Equity Average surged 1181.73% in 2022, then slumped 358.44% in 2026.
• A 5-year view of Equity Average shows it stood at $29.1 million in 2022, then surged by 72.39% to $50.1 million in 2023, then tumbled by 59.05% to $20.5 million in 2024, then plunged by 48.04% to $10.7 million in 2025, then sank by 243.04% to -$15.2 million in 2026.
• Business Quant data shows IRD's Equity Average at -$15.2 million in Q1 2026, $10.7 million in Q4 2025, and $11.7 million in Q3 2025.